 |
BioMS, an Edmonton-based biotechnology company in Canada, has announced it has received permission from the US Food and Drug Administration (FDA) to carry out a phase III clinical trial of its experimental drug MBP8298 as a potential treatment for secondary-progressive MS.
The study is already underway in Canada, the United Kingdom, Denmark and Sweden.
For more information, please click on the link below.
Source: MS Society of Canada
Weblink: click here
|
